Vascular Solutions 10-Q 25 Apr 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 21, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	VASCULAR SOLUTIONS INC
Entity Central Index Key	1,030,206
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		17,371,153
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016

Consolidated Balance Sheets (un

Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 30,958	$ 41,491
Accounts receivable, net of reserves of $315 and $360 in 2016 and 2015, respectively	21,485	19,121
Inventories	22,629	22,105
Prepaid expenses and other	4,848	4,361
Total current assets	79,920	87,078
Property, plant and equipment, net	36,254	34,508
Goodwill	10,089	10,045
Intangible assets, net	8,060	8,445
Deferred tax assets, net of liabilities	5,434	4,797
Total assets	139,757	144,873
Current liabilities:
Accounts payable	4,550	5,830
Accrued compensation	6,031	6,702
Accrued expenses	2,765	4,125
Total current liabilities	13,346	16,657
Long-term deferred tax liabilities	74	72
Total long-term liabilities	74	72
Shareholders' equity:
Common stock, $0.01 per share par value: Authorized shares - 40,000,000 Issued and outstanding shares - 17,371,153 - 2016; 17,386,853 - 2015	174	174
Additional paid-in capital	100,511	102,123
Other	(1,126)	(1,186)
Accumulated earnings	26,778	27,033
Total shareholders' equity	126,337	128,144
Total liabilities and shareholders' equity	$ 139,757	$ 144,873

Consolidated Balance Sheets (u3

Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Reserves for accounts receivable	$ 315	$ 360
Shareholders' equity:
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized shares (in shares)	40,000,000	40,000,000
Common stock, shares issued (in shares)	17,371,153	17,386,853
Common stock, shares outstanding (in shares)	17,371,153	17,386,853

Consolidated Statements of Earn

Consolidated Statements of Earnings (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net revenue:
Product revenue	$ 39,242	$ 34,441
License, royalty and collaboration revenue	136	170
Total revenue	39,378	34,611
Product costs and operating expenses:
Cost of goods sold	13,571	11,296
Collaboration expenses	27	54
Research and development	5,026	4,067
Clinical and regulatory	1,997	1,481
Sales and marketing	9,599	8,732
General and administrative	9,644	4,777
Medical device excise taxes	0	376
Amortization of purchased technology and intangibles	404	405
Total product costs and operating expenses	40,268	31,188
Operating earnings (loss)	(890)	3,423
Other earnings	16	28
Earnings (loss) before income taxes	(874)	3,451
Income tax benefit (expense)	619	(1,244)
Net earnings (loss)	$ (255)	$ 2,207
Net earnings (loss) per share - basic (in dollars per share)	$ (0.01)	$ 0.13
Net earnings (loss) per share - diluted (in dollars per share)	$ (0.01)	$ 0.12

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Earnings (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Consolidated Statements of Comprehensive Earnings (Loss) (unaudited)
Net earnings (loss)	$ (255)	$ 2,207
Other comprehensive earnings (loss), net of tax of $0:Foreign currency translation adjustments	60	(712)
Comprehensive earnings (loss)	$ (195)	$ 1,495

Consolidated Statements of Com6

Consolidated Statements of Comprehensive Earnings (Loss) (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Consolidated Statements of Comprehensive Earnings (Loss) (unaudited)
Foreign currency translation adjustments	$ 0	$ 0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities
Net earnings (loss)	$ (255)	$ 2,207
Adjustments to reconcile net earnings (loss) to net cash provided by (used in) operating activities:
Depreciation	1,186	1,048
Amortization	404	405
Stock-based compensation	1,653	1,511
Deferred taxes, net	(637)	638
Tax benefit from stock-based awards	0	(248)
Change in accounts receivable allowance	(45)	55
Changes in operating assets and liabilities:
Accounts receivable	(2,311)	(1,102)
Inventories	(524)	(2,089)
Prepaid expenses and other	(484)	128
Accounts payable	(1,286)	1,482
Accrued expenses	(2,036)	865
Net cash provided by (used in) operating activities	(4,335)	4,900
Investing activities
Purchase of property and equipment	(2,914)	(2,661)
Purchase of building and land	0	(2,748)
Net cash used in investing activities	(2,914)	(5,409)
Financing activities
Repurchase of common shares	(3,344)	(1,951)
Tax benefit from stock-based awards	0	248
Proceeds from the exercise of stock options	79	162
Net cash used in financing activities	(3,265)	(1,541)
Decrease in cash and cash equivalents	(10,514)	(2,050)
Effect of exchange rate changes on cash and cash equivalents	(19)	(244)
Cash and cash equivalents at beginning of period	41,491	36,461
Cash and cash equivalents at end of period	30,958	34,167
Supplemental disclosure of cash flow
Cash paid for taxes	$ 94	$ 256

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Basis of Presentation [Abstract]
Basis of Presentation	(1) Basis of Presentation The accompanying unaudited consolidated financial statements of Vascular Solutions, Inc. (the Company) have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal, recurring adjustments considered necessary for a fair presentation have been included. The consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission. Interim results of operations are not necessarily indicative of the results to be expected for the full year or any other interim periods.

Net Earnings (Loss) per Share

Net Earnings (Loss) per Share	3 Months Ended
	Mar. 31, 2016
Net Earnings (Loss) per Share [Abstract]
Net Earnings (Loss) per Share	(2) Net Earnings (Loss) per Share In accordance with Accounting Standards Codification (ASC) Topic 260, Earnings Per Share Weighted average common shares outstanding for the three months ended March 31, 2016 and 2015 were as follows: Three Months Ended March 31, 2016 2015 Weighted average shares outstanding – basic 17,105,000 16,939,000 Weighted average shares outstanding – diluted 17,105,000 17,940,000

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2016
Revenue Recognition [Abstract]
Revenue Recognition	(3) Revenue Recognition In the United States, the Company sells its products and services directly to hospitals and clinics. Revenue is recognized in accordance with generally accepted accounting principles as outlined in ASC Topic 605-10-S99, Revenue Recognition In all international markets, the Company sells its products to international distributors which subsequently resell the products to hospitals and clinics. The Company has agreements with each of its distributors which provide that title and risk of loss pass to the distributor upon shipment of the products to the distributor. The Company warrants that its products are free from manufacturing defects at the time of shipment to the distributor. Revenue is recognized upon shipment of products to distributors following the receipt and acceptance of a distributor’s purchase order and is reported on a gross basis. Allowances are provided for estimated returns and costs at the time of shipment. Sales and use taxes are reported on a net basis, excluding them from revenue. The Company’s revenues from license agreements and research collaborations are recognized when earned. In accordance with ASC Topic 605, for revenues which contain multiple deliverables, the Company separates the deliverables into separate accounting units if they meet the following criteria: (i) the delivered items have a stand-alone value to the customer; (ii) the fair value of any undelivered items can be reliably determined; and (iii) if the arrangement includes a general right of return, delivery of the undelivered items is probable and substantially controlled by the seller. Deliverables that do not meet these criteria are combined with one or more other deliverables into one accounting unit. Revenue from each accounting unit is recognized based on the applicable accounting literature, primarily ASC Topic 605. The Company currently has a license agreement with King Pharmaceuticals, Inc. (King), now a subsidiary of Pfizer, Inc., under which the Company licensed the exclusive rights of Thrombi-Pad TM ® TM Starting in January 2012, the Company began to generate revenue from selling a reprocessing service for ClosureFAST ® In addition, the Company has reviewed the provisions of ASC Topic 808, Collaborative Arrangements In accordance with ASC Topic 605-45-45, the Company includes shipping and handling revenues in net revenue, and shipping and handling costs in cost of goods sold.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2016
Inventories [Abstract]
Inventories	(4) Inventories Inventories are stated at the lower of cost (weighted average first-in, first-out method) or market. Appropriate consideration is given to deterioration, obsolescence and other factors in evaluating net realizable value. Inventories are comprised of the following: March 31, 2016 December 31, 2015 (dollars in thousands) Raw materials $ 11,430 $ 10,760 Work-in-process 2,494 1,789 Finished goods 8,705 9,556 $ 22,629 $ 22,105

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	3 Months Ended
	Mar. 31, 2016
Goodwill and Other Intangible Assets [Abstract]
Goodwill and Other Intangible Assets	(5) Goodwill and Other Intangible Assets The changes in the carrying amount of goodwill and acquired intangible assets for the three months ended March 31, 2016 are as follows: Goodwill Acquired Intangibles (dollars in thousands) Balance at December 31, 2015 $ 10,045 $ 8,445 Amortization – (404 ) Foreign currency translation adjustments 44 19 Balance at March 31, 2016 $ 10,089 $ 8,060

Credit Risk and Allowance for D

Credit Risk and Allowance for Doubtful Accounts	3 Months Ended
	Mar. 31, 2016
Credit Risk and Allowance for Doubtful Accounts [Abstract]
Credit Risk and Allowance for Doubtful Accounts	(6) Credit Risk and Allowance for Doubtful Accounts The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. This allowance is regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay. Accounts receivable over 30 days past due are considered past due. The Company does not accrue interest on past due accounts receivable. Receivables are written off only after all collection attempts have failed and are based on individual credit evaluation and the specific circumstances of the customer. At March 31, 2016 and December 31, 2015, the allowance for doubtful accounts was $235,000 and $285,000, respectively. All product returns must be pre-approved and, if approved, customers are subject to a 20% restocking charge. The Company analyzes the rate of historical returns when evaluating the adequacy of the allowance for sales returns, which is included with the allowance for doubtful accounts on its balance sheet. At March 31, 2016 and December 31, 2015, the sales and return allowance was $80,000 and $75,000, respectively. Accounts receivable are shown net of the combined total of the allowance for doubtful accounts and allowance for sales returns of $315,000 and $360,000 at March 31, 2016 and December 31, 2015, respectively.

Concentrations of Credit and Ot

Concentrations of Credit and Other Risks	3 Months Ended
	Mar. 31, 2016
Concentrations of Credit and Other Risks [Abstract]
Concentrations of Credit and Other Risks	(7) Concentrations of Credit and Other Risks In the United States, the Company sells its products directly to hospitals and clinics. In all international markets, the Company sells its products to distributors who, in turn, sell to hospitals and clinics. Loss or termination of distributors, or their inability to effectively promote the Company’s products, could have a material adverse effect on the Company’s financial condition and results of operations. With respect to accounts receivable, the Company performs credit evaluations of its customers and does not require collateral to extend credit to an account. No customer represented more than 10% of gross accounts receivable at March 31, 2016 or December 31, 2015. There have been no material losses on customer receivables. Sales by geographic location are based on the location of the customer. Product revenue by geographic destination as a percentage of total product revenues for the three months ended March 31, 2016 and 2015 was 80% and 78% in the United States and 20% and 22% in international markets, respectively. No single customer represented greater than 10% of the total net revenue for the three months ended March 31, 2016 or 2015.

Dependence on Key Suppliers

Dependence on Key Suppliers	3 Months Ended
	Mar. 31, 2016
Dependence on Key Suppliers [Abstract]
Dependence on Key Suppliers	(8) Dependence on Key Suppliers The Company purchases certain key components from single-source suppliers. Any significant component delay or interruption could require the Company to qualify new sources of supply, if available, and could have a material adverse effect on the Company’s financial condition and results of operations. King Pharmaceuticals The Company purchases its requirements for thrombin (a component in the Hemostat products) under a Thrombin-JMI Supply Agreement entered into with King on January 9, 2007. Under the terms of the Thrombin-JMI Supply Agreement, King agrees to manufacture and supply thrombin to the Company on a non-exclusive basis. The Thrombin-JMI Supply Agreement does not contain any minimum purchase requirements. King agrees to supply the Company with such quantity of thrombin as the Company may order at a fixed price throughout the term of the Thrombin-JMI Supply Agreement as adjusted for inflation, variations in potency and other factors. The Thrombin-JMI Supply Agreement has an initial term of 10 years, followed by successive automatic one-year extensions, subject to termination by the parties under certain circumstances, including: (i) termination by King without cause any time after the fifth anniversary of the date of the Thrombin-JMI Supply Agreement upon five years prior written notice to the Company, and (ii) termination by the Company without cause any time after the fifth anniversary of the date of the Thrombin-JMI Supply Agreement upon five years prior written notice to King provided that the Device Supply Agreement, which the Company also entered into with King on January 9, 2007, has expired on its terms or the parties have agreed to terminate it.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies [Abstract]
Commitments and Contingencies	(9) Commitments and Contingencies From time to time, the Company is involved in legal proceedings arising in the normal course of business. As of the date of this report, the Company is not a party to any legal proceeding in which an adverse outcome would reasonably be expected to have a material adverse effect on the Company’s results of operations or financial condition.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Taxes [Abstract]
Income Taxes	(10) Income Taxes The Company is subject to income tax in numerous jurisdictions and at various rates and the use of estimates is required in determining the provision for income taxes. For the three months ended March 31, 2016, the Company recorded an income tax benefit of $619,000 on a loss before tax of $874,000, resulting in an effective tax benefit rate of 70.8%. For the three months ended March 31, 2015, the Company recorded a provision for taxes of $1,244,000 on earnings before tax of $3,451,000 resulting in an effective income tax rate of 36%. The effective tax benefit rate of 70.8% for the three months ended March 31, 2016 is higher than the Company’s effective tax rate of 33.5% due to the first quarter adoption of Accounting Standards Update (ASU) No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting The Company regularly assesses the likelihood that the deferred tax assets will be recovered from future taxable earnings. The Company considers projected future taxable earnings and ongoing tax planning strategies, and then records a valuation allowance to reduce the carrying value of the net deferred taxes to an amount that is more likely than not to be realized. If the Company’s actual results and updated projections vary significantly from the projections used as a basis for determining its valuation allowance, the Company may need to increase or decrease the valuation allowance against the gross deferred tax assets. The Company will adjust earnings for the deferred tax in the period in which any such determination is made. The Company applies ASC Topic 740, Income Taxes The Company is subject to income tax examinations in the U.S. Federal jurisdiction, as well as in the Republic of Ireland and various state jurisdictions. U.S. Federal and state tax years that remain open to examination at March 31, 2016 are 2013 through 2015.

Recently Issued Accounting Pron

Recently Issued Accounting Pronouncements	3 Months Ended
	Mar. 31, 2016
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements	(11) Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued guidance creating ASC Topic 606, Revenue from Contracts with Customers In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330) Related to Simplifying the Measurement of Inventory, In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) Related to the Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU 2016-02, Leases, to increase transparency and comparability among organizations by recognizing all lease transactions (with terms in excess of 12 months) on the balance sheet as a lease liability and a right-of-use asset (as defined). The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted. Upon adoption, the lessee will apply the new standard retrospectively to all periods presented or retrospectively using a cumulative effect adjustment in the year of adoption. The Company is currently assessing the effect that adoption will have on the consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting

Products and Services

Products and Services	3 Months Ended
	Mar. 31, 2016
Products and Services [Abstract]
Products and Services	(12) Products and Services In order to present a more detailed product-specific revenue analysis, in the first quarter of 2015, the Company began reporting net revenue for each of its top products in each of its primary markets. The following table sets forth, for the periods indicated, net revenue by product along with the percent change from the previous year’s corresponding period for each of the Company’s top eight products by net revenue: Three months ended March 31, 2016 2015 Product Primary Market Net Revenue Percent Change Net Revenue (dollars in thousands) GuideLiner ® Interventional cardiology $ 11,658 13 % $ 10,340 Micro-introducer kits Interventional radiology 3,569 25 % 2,854 Pronto ® Interventional cardiology 3,403 (22 %) 4,382 Vein catheter reprocessing Phlebology 2,989 10 % 2,712 Hemostatic patches Interventional cardiology 2,845 (6 %) 3,022 Turnpike ® Interventional cardiology 2,297 1392 % 154 Radial access products Interventional cardiology 2,099 28 % 1,638 Langston ® Interventional cardiology 1,882 19 % 1,578 The Company sells its products into four primary clinical markets: interventional cardiology, interventional radiology, electrophysiology, and phlebology (vein treatment). The following table sets forth, for the periods indicated, net revenue percentage by primary clinical market: Three months ended March 31, 2016 2015 Primary Market Revenue Percentage Revenue Percentage Interventional cardiology 74 % 73 % Phlebology 13 % 13 % Interventional radiology 9 % 10 % Electrophysiology 4 % 4 % 100 % 100 %

Net Earnings (Loss) per Share (

Net Earnings (Loss) per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Net Earnings (Loss) per Share [Abstract]
Weighted average common shares outstanding	Weighted average common shares outstanding for the three months ended March 31, 2016 and 2015 were as follows: Three Months Ended March 31, 2016 2015 Weighted average shares outstanding – basic 17,105,000 16,939,000 Weighted average shares outstanding – diluted 17,105,000 17,940,000

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2016
Inventories [Abstract]
Inventories	Inventories are comprised of the following: March 31, 2016 December 31, 2015 (dollars in thousands) Raw materials $ 11,430 $ 10,760 Work-in-process 2,494 1,789 Finished goods 8,705 9,556 $ 22,629 $ 22,105

Goodwill and Other Intangible22

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill and Other Intangible Assets [Abstract]
Goodwill and acquired intangible assets	The changes in the carrying amount of goodwill and acquired intangible assets for the three months ended March 31, 2016 are as follows: Goodwill Acquired Intangibles (dollars in thousands) Balance at December 31, 2015 $ 10,045 $ 8,445 Amortization – (404 ) Foreign currency translation adjustments 44 19 Balance at March 31, 2016 $ 10,089 $ 8,060

Products and Services (Tables)

Products and Services (Tables)	3 Months Ended
	Mar. 31, 2016
Products and Services [Abstract]
Revenue by product category	The following table sets forth, for the periods indicated, net revenue by product along with the percent change from the previous year’s corresponding period for each of the Company’s top eight products by net revenue: Three months ended March 31, 2016 2015 Product Primary Market Net Revenue Percent Change Net Revenue (dollars in thousands) GuideLiner ® Interventional cardiology $ 11,658 13 % $ 10,340 Micro-introducer kits Interventional radiology 3,569 25 % 2,854 Pronto ® Interventional cardiology 3,403 (22 %) 4,382 Vein catheter reprocessing Phlebology 2,989 10 % 2,712 Hemostatic patches Interventional cardiology 2,845 (6 %) 3,022 Turnpike ® Interventional cardiology 2,297 1392 % 154 Radial access products Interventional cardiology 2,099 28 % 1,638 Langston ® Interventional cardiology 1,882 19 % 1,578 The following table sets forth, for the periods indicated, net revenue percentage by primary clinical market: Three months ended March 31, 2016 2015 Primary Market Revenue Percentage Revenue Percentage Interventional cardiology 74 % 73 % Phlebology 13 % 13 % Interventional radiology 9 % 10 % Electrophysiology 4 % 4 % 100 % 100 %

Net Earnings (Loss) per Share24

Net Earnings (Loss) per Share (Details) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net Earnings (Loss) per Share [Abstract]
Weighted average shares outstanding - basic (in shares)	17,105,000	16,939,000
Weighted average shares outstanding - diluted (in shares)	17,105,000	17,940,000

Revenue Recognition (Details)

Revenue Recognition (Details)	3 Months Ended
	Mar. 31, 2016
Thrombi Pad [Member]
Revenue Recognition, Amortization of License Fee [Line Items]
Years to amortize license fees	10 years
Thrombi Paste [Member]
Revenue Recognition, Amortization of License Fee [Line Items]
Years to amortize license fees	10 years

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventories [Abstract]
Raw materials	$ 11,430	$ 10,760
Work-in-process	2,494	1,789
Finished goods	8,705	9,556
Inventory, Total	$ 22,629	$ 22,105

Goodwill and Other Intangible27

Goodwill and Other Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Goodwill [Abstract]
Beginning balance	$ 10,045
Foreign currency translation adjustments	44
Ending balance	10,089
Acquired Intangibles [Abstract]
Beginning balance	8,445
Amortization	(404)	$ (405)
Foreign currency translation adjustments	19
Ending balance	$ 8,060

Credit Risk and Allowance for28

Credit Risk and Allowance for Doubtful Accounts (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Valuation and Qualifying Accounts Disclosure [Line Items]
Number of days outstanding before being considered past due	30 days
Restocking charge	20.00%
Reserves for accounts receivable, net	$ 315,000	$ 360,000
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Reserves for accounts receivable, net	235,000	285,000
Sales Return Allowances [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Reserves for accounts receivable, net	$ 80,000	$ 75,000

Concentrations of Credit and 29

Concentrations of Credit and Other Risks (Details)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Concentration Risk [Line Items]
Concentration risk, percentage	100.00%	100.00%
United States [Member] | Product Revenue [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	80.00%	78.00%
International Markets [Member] | Product Revenue [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	20.00%	22.00%

Dependence on Key Suppliers (De

Dependence on Key Suppliers (Details)	3 Months Ended
	Mar. 31, 2016
Kings Pharmaceuticals [Abstract]
Initial agreement period	10 years
Contract extension period	1 year
Period of written notice to supplier	5 years

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Income Taxes [Abstract]
Income tax benefit (expense)	$ 619,000	$ (1,244,000)
Earnings (loss) before income tax	$ (874,000)	$ 3,451,000
Effective income tax rate	70.80%	36.00%
Federal statutory income tax rate	33.50%	34.00%
Recognized excess tax benefits	$ 326,000
Unrecognized income tax asset	379,000		$ 379,000
Tax related interest expense	0
Tax related penalties expense	$ 0

Products and Services (Details)

Products and Services (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)ProductMarket	Mar. 31, 2015USD ($)
Product Information [Line Items]
Number of products | Product	8
Number of primary markets | Market	4
Total revenue	$ 39,378	$ 34,611
Percentage of sales revenue	100.00%	100.00%
Interventional cardiology [Member]
Product Information [Line Items]
Percentage of sales revenue	74.00%	73.00%
Phlebology [Member]
Product Information [Line Items]
Percentage of sales revenue	13.00%	13.00%
Interventional radiology [Member]
Product Information [Line Items]
Percentage of sales revenue	9.00%	10.00%
Electrophysiology [Member]
Product Information [Line Items]
Percentage of sales revenue	4.00%	4.00%
GuideLiner catheters [Member]
Product Information [Line Items]
Class of primary market description	Interventional cardiology
Total revenue	$ 11,658	$ 10,340
Total revenue percentage change	13.00%
Micro-introducer kits [Member]
Product Information [Line Items]
Class of primary market description	Interventional radiology
Total revenue	$ 3,569	2,854
Total revenue percentage change	25.00%
Pronto catheters [Member]
Product Information [Line Items]
Class of primary market description	Interventional cardiology
Total revenue	$ 3,403	4,382
Total revenue percentage change	(22.00%)
Vein catheter reprocessing [Member]
Product Information [Line Items]
Class of primary market description	Phlebology
Total revenue	$ 2,989	2,712
Total revenue percentage change	10.00%
Hemostatic patches [Member]
Product Information [Line Items]
Class of primary market description	Interventional cardiology
Total revenue	$ 2,845	3,022
Total revenue percentage change	(6.00%)
Turnpike catheters [Member]
Product Information [Line Items]
Class of primary market description	Interventional cardiology
Total revenue	$ 2,297	154
Total revenue percentage change	1392.00%
Radial access products [Member]
Product Information [Line Items]
Class of primary market description	Interventional cardiology
Total revenue	$ 2,099	1,638
Total revenue percentage change	28.00%
Langston catheters [Member]
Product Information [Line Items]
Class of primary market description	Interventional cardiology
Total revenue	$ 1,882	$ 1,578
Total revenue percentage change	19.00%